Optical endomicroscopy and the road to real-time, in vivo pathology: present and future
- First Online:
- Cite this article as:
- Carignan, C.S. & Yagi, Y. Diagn Pathol (2012) 7: 98. doi:10.1186/1746-1596-7-98
- 5.4k Downloads
Epithelial cancers account for substantial mortality and are an important public health concern. With the need for earlier detection and treatment of these malignancies, the ability to accurately detect precancerous lesions has an increasingly important role in controlling cancer incidence and mortality. New optical technologies are capable of identifying early pathology in tissues or organs in which cancer is known to develop through stages of dysplasia, including the esophagus, colon, pancreas, liver, bladder, and cervix. These diagnostic imaging advances, together as a field known as optical endomicroscopy, are based on confocal microscopy, spectroscopy-based imaging, and optical coherence tomography (OCT), and function as “optical biopsies,” enabling tissue pathology to be imaged in situ and in real time without the need to excise and process specimens as in conventional biopsy and histopathology. Optical biopsy techniques can acquire high-resolution, cross-sectional images of tissue structure on the micron scale through the use of endoscopes, catheters, laparoscopes, and needles. Since the inception of these technologies, dramatic technological advances in accuracy, speed, and functionality have been realized. The current paradigm of optical biopsy, or single-area, point-based images, is slowly shifting to more comprehensive microscopy of larger tracts of mucosa. With the development of Fourier-domain OCT, also known as optical frequency domain imaging or, more recently, volumetric laser endomicroscopy, comprehensive surveillance of the entire distal esophagus is now achievable at speeds that were not possible with conventional OCT technologies. Optical diagnostic technologies are emerging as clinically useful tools with the potential to set a new standard for real-time diagnosis. New imaging techniques enable visualization of high-resolution, cross-sectional images and offer the opportunity to guide biopsy, allowing maximal diagnostic yields and appropriate staging without the limitations and risks inherent with current random biopsy protocols. However, the ability of these techniques to achieve widespread adoption in clinical practice depends on future research designed to improve accuracy and allow real-time data transmission and storage, thereby linking pathology to the treating physician. These imaging advances are expected to eventually offer a see-and-treat paradigm, leading to improved patient care and potential cost reduction.
The virtual slide(s) for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs/5372548637202968
KeywordsBarrett’s esophagusCancerConfocal microscopyDysplasiaEndoscopyIn vivo imagingNeoplasiaOptical coherence tomographyOptical imaging
Angle-resolved low-coherence interferometry
Confocal laser endomicroscopy
Endoscope-based confocal laser endomicroscopy
Optical coherence tomography
Probe-based confocal laser endomicroscopy
Spectrally encoded confocal microscopy
Volumetric laser endomicroscopy.
Cancers affecting the mucosal tracts are a substantial public health concern. Indeed, the incidence of esophageal adenocarcinoma (EAC) has increased dramatically in the United States[1, 2] as well as most other Western developed societies. The increased incidence is particularly alarming among US white men, which jumped 463% between 1975 and 2004; increases have also been observed in Europe, Australia, and New Zealand. Age-standardized rates of EAC have increased up to 40% every 5 years in England and Wales, while annual increases in incidence rates of up to 5%, 5%, 6%, and 12% have been observed in Scotland, Scandinavia, France, and Switzerland, respectively[1, 3, 5, 6]. EAC has a substantial impact on mortality, with a low 5-year survival rate (16.8%); overall, esophageal cancer has become the eighth most common cause of cancer death worldwide[1, 3]. In contrast to esophageal cancer, the overall incidence rates of colorectal and cervical cancers have declined in the past several decades, but rates of gastric adenocarcinoma have remained relatively stable. Despite these trends, colorectal cancer is still the third most common cancer worldwide, with the highest age-standardized incidence rates in Australia/New Zealand (45.7 per 100,000 men) and Western and Southern Europe (41.2 and 39.3 per 100,000 men, respectively). Colorectal cancer is the third leading cause of cancer mortality in men and women in the United States and accounts for 8% of all cancer deaths worldwide, with the highest mortality rates in Central and Eastern Europe. Cervical cancer is the third most common cancer in women, with an estimated 530,000 new cases worldwide in 2008; incidence and mortality are lower in more developed areas such as Europe and North America than in developing countries in Africa and South America. Gastric cancer is the fourth most common malignancy in the world (989,000 new cases occurring in 2008) and the second leading cause of cancer death (738,000 deaths worldwide), with the highest mortality rates in Eastern Asia and Central and Eastern Europe.
Given the incidence and mortality associated with epithelial cancers, effective strategies for early detection and treatment of premalignant lesions are essential. The benefits of early detection have been clearly demonstrated in cervical cancer, with population-based and cohort studies indicating that regular Pap screenings have decreased cervical cancer incidence and mortality by at least 80%. Similarly, Barrett’s esophagus (BE) has been recognized as the premalignant lesion of EAC[13, 14]. A growing number of studies have shown that regular endoscopic BE surveillance identifies patients with earlier stage cancer[15–17], leading to higher survival rates than more advanced disease. Several retrospective studies have indicated that survival is prolonged if esophageal cancers are detected by endoscopic surveillance rather than by presenting symptoms[13, 15, 18].
This review discusses the substantial progress under way in endoscopic imaging, including the present state of technology, current approaches to imaging research, and the potential impact of these techniques on daily clinical practice in the near future.
Paradigms in endoscopic biopsy: applications and limitations
Current approaches to endoscopic biopsy use external imaging, such as computed tomography (CT), magnetic resonance (MR), or white light endoscopy, to image suspect tissue. Despite advances in the field of endoscopic imaging, technical limitations of these modalities exist. These limitations may have important clinical implications, especially in optimizing cancer screening, diagnosis, and surveillance in the detection and histological assessment of premalignant lesions. For example, treatment guidelines for recognizing EAC and preventing mortality are largely based on endoscopic surveillance of patients with chronic, symptomatic gastroesophageal reflux disease and those with BE as well as use of histopathological assessment to evaluate the risk of BE progression to EAC[13, 14, 19]. Although currently considered the gold standard for surveillance, white light endoscopy is limited to the surface of the mucosa and depends on clinical changes to signify underlying disease. External sources (CT/MR) typically lack sufficient resolution to provide accurate guidance for biopsy location determination.
When BE is identified, targeted biopsies and four-quadrant, random biopsies are obtained to detect invisible neoplasias[14, 19, 20], but these strategies may be unreliable because of sampling error and other practical limitations. When performed appropriately, a random sampling technique reduces the area of tissue surveyed, covering as little as 5% of the surface area of BE tissue. Mucosal irregularities of early neoplasias are often discrete and easily missed during standard BE surveillance endoscopy. In surgical resection specimens, up to 43% of patients with confirmed high-grade dysplasia had adenocarcinomas that were missed before surgery, despite the use of endoscopic biopsy. Given the small amounts of histologically ambiguous tissue retrieved, the potential for diagnostic misinterpretation and variability among pathologists is considerable, a problem that has been demonstrated in several studies[22, 24–26]. The time delay between endoscopy and diagnosis is another limitation, with separate procedures required for the detection and treatment of dysplasia. The current biopsy approach is uncomfortable and time consuming for patients, often requiring a lengthy period of sedation and posing risks of bleeding and perforation[20, 27]. The limitations of current imaging and biopsy methods represent an unmet need in the early detection of mucosal dysplasias.
Current and investigational technologies for in vivo imaging
Comparison of current and investigational imaging technologies
Field of view
Radio nucleotide, DOT, PET
MRI, CT, US
EUS, IVMRI, X-ray
Standard and high-definition video endoscopes
SECM, Micro OCT, FFOCM
Confocal laser endomicroscopy
Confocal laser endomicroscopy (CLE), a recent endoscopic advance, allows real-time high-resolution histologic analysis of targeted tissue during endoscopy. The CLE illuminates tissue with a low-powered laser focused by an objective lens into a single point within a fluorescent specimen[30, 31]. A confocal microscope is used to exclude light above and below a plane of interest, thus allowing for an optical section to be observed, similar to a histologic tissue section. The generated gray scale image represents one focal plane within the examined specimen. The mucosa typically can be imaged to a depth of 100 to 150 μm with this technique.
Although commercially available, the place of CLE in current diagnostic paradigms versus a conventional histopathological examination is still evolving. With appropriate contrast agents, CLE has the potential for subcellular resolution, reducing the number of biopsies required, as well as for molecular characterization. However, available CLE devices have a narrow field of view and cannot penetrate beyond the mucosa, allowing visualization of only superficial mucosal layers[29, 30]. Moreover, CLE does not provide an archive of tissue for full molecular characterization, and contrast agents can limit the procedure duration and ability to obtain repeat images.
Spectrally encoded confocal microscopy
Recent clinical studies have explored a/LCI in the assessment of dysplasia in esophageal and intestinal tissues. In the first in vivo clinical study of a/LCI, 46 patients undergoing routine endoscopic surveillance for BE were scanned with the a/LCI system and the results correlated with an endoscopic biopsy specimen. The nuclear size measurements generated for deep epithelial tissue (200–300 μm beneath the surface) separated dysplastic from non-dysplastic tissue with an accuracy of 86%, using a cutoff of 11.84 μm to separate the two types. Using this same cutoff, a/LCI distinguished dysplastic BE specimens from indeterminate and non-dysplastic BE with a sensitivity of 100% (13/13; 95% confidence interval [CI], 0.75–100) and a specificity of 85% (76/89; 95% CI, 0.76–0.92). Similarly, a pilot ex vivo study of 27 patients undergoing partial colonic resection demonstrated high diagnostic value of this method at a depth 200 to 300 μm beneath the mucosal surface, with a/LCI separating dysplastic from healthy intestinal tissues with a sensitivity of 92.9%, a specificity of 83.6%, and an overall accuracy of 85.2%.
Several other spectroscopy-based imaging techniques are under investigation in various clinical applications. Laser-induced fluorescence is a technique based on the principle that certain compounds exhibit a characteristic fluorescence emission when excited by light. This technology has been shown to detect malignant colonic tissue and to distinguish malignant tissue from metaplastic and normal tissue in BE[56, 58]. Multimodal hyperspectroscopy is based on tissue fluorescence and reflected light measurements, which are analyzed with computed-based algorithms to differentiate between abnormal and normal tissues. Although more extensively explored for use in detecting cervical cancer[59, 60], clinical studies in BE patients are under way.
Optical coherence tomography
OCT is an imaging technique first introduced for use in biological tissues in 1991 that generates high-resolution, cross-sectional, subsurface images by using low-coherence interferometry to measure the echo time delay and intensity of back-scattered light. OCT is analogous to ultrasonography, except that OCT measures the intensity of infrared light rather than sound waves. With OCT, depth intensity is measured by time-domain measurements, allowing for image construction for all three dimensions.
Several OCT systems are currently in use or under investigation. The original OCT technology, now called time-domain OCT (Niris®, Imalux Corporation, Cleveland, OH, USA)[80, 81], has been described in detail elsewhere[64, 78]. Interferometric synthetic aperture microscopy uses computed imaging and synthetic aperture techniques to modify OCT signals to achieve three-dimensional, spatially invariant resolution for all depths in a cross-sectional scan[82–84]. The feasibility of using this technology to image human breast tissue has recently been demonstrated[83, 84].
Despite the diagnostic potential of time-domain OCT, its relatively slow imaging speed has precluded its ability to survey large areas of the GI tract, limiting its use to point-sampling with a field of view comparable to that of conventional biopsy[70, 85]. However, a new technologic approach to OCT allows dramatic increases in imaging speed without compromising image resolution or quality[70, 86–88]. This technology, referred to as Fourier-domain OCT or optical frequency domain imaging, is also called volumetric laser endomicroscopy (VLE). VLE acquires cross-sectional images by using a focused, narrow-diameter beam to repeatedly measure the delay of reflections from within the tissue sample. Interferometry is used to measure the delay intervals, while Fourier transformation is used to compute traditional A-lines, or depth scans, which comprise the tissue reflectivity as a function of depth along the beam. Unlike time-domain OCT, VLE uses a fixed wavelength or swept-source technology in which the wavelength of a monochromatic light source is rapidly scanned to measure the interference signal as a function of wavelength[70, 87].
The use of a balloon-based VLE system with helically scanning optics for esophageal imaging has been described[68–70, 85]. With this system, the optical components of the catheter are positioned with the esophageal lumen via a balloon-centered probe[70, 85]. After the balloon is inflated, the distal esophagus is dilated and the imaging optics become centered. Optics are slowly pulled back during the imaging procedure while the imaging optics are rotated by a probe scanner; thus, the entire portion of the esophageal lumen that was in contact with the balloon is scanned in a helical or circumferential fashion. Real-time, volumetric images are obtained by scanning the imaging beam over the tissue surface in two dimensions.
Roles and impact of the advances in optical biopsy
In vivo pathology imaging devices and the rapid evolution of the technology have the potential to make real-time diagnosis the new standard, with immediate diagnosis and management during endoscopy. The new optical biopsy technologies provide better quality, detailed, high-resolution images and allow visualization of living cells and cellular structures at and below the mucosal surface during ongoing endoscopy[28, 35]. The convergence of imaging and pathology may provide distinct advantages in cancer detection and diagnosis without the limitations and risks inherent with biopsy procedures. With these technologies, maximal diagnostic yields may be obtained, leading to appropriate staging through guided biopsy while minimizing the frequency and error potential of random biopsy protocols. In vivo cellular information can be delivered before biopsies are performed, or imaging files may be transmitted with biopsies, potentially improving the efficiency and accuracy of diagnosis.
Despite the potential these techniques may offer to standard clinical practice, barriers remain. Optical biopsy techniques can identify neoplastic changes in a variety of biologic tissues, but prospective studies in large cohorts are needed to establish concrete sensitivity and specificity of the respective technologies, in each target organ, versus the need for biopsy. To achieve widespread clinical adoption, these technologies must be accurate, efficient for use in the endoscopic setting, reliable, user-friendly, patient-friendly, and cost-effective[22, 89]. Wide acceptance and interpretation capabilities, which require comprehensive physician education and training, are also necessary to establish appropriate comfort with use. Investigators are currently working to improve the accuracy, speed, and ease of interpretation of these technologies. In addition, research is under way to allow real-time data transmission and storage, thereby linking pathology results to the treating physician.
As epithelial malignancies move toward earlier detection and treatment, the ability to accurately detect precancerous lesions has an increasingly important role in controlling cancer incidence and mortality. With new optical techniques, high-resolution images of early neoplastic changes in various tissues and organs can now be captured in real time through endoscopes, catheters, laparoscopes, and needles. Although the diagnostic potential of these technologies is rapidly expanding, their clinical adoption will depend on present and future research demonstrating improved imaging performance and functionality, and the development and acceptance of new guidelines for imaging. Novel optical imaging technology offers the opportunity to utilize a see-and-treat paradigm, potentially leading to improved patient care and cost reduction.
We thank Albert Balkiewicz, MSc, who provided medical writing services through Peloton Advantage, LLC, on behalf of the authors and NinePoint Medical. The authors were fully responsible for the content, editorial decisions, and opinions expressed in the current article. Neither author received an honorarium related to the development of this manuscript.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.